TY - JOUR
T1 - Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study)
AU - Eshleman, Susan H.
AU - Becker-Pergola, Graziella
AU - Deseyve, Martin
AU - Guay, Laura A.
AU - Mracna, Martin
AU - Fleming, Thomas
AU - Cunningham, Shawn
AU - Musoke, Philippa
AU - Mmiro, Francis
AU - Jackson, J. Brooks
N1 - Funding Information:
Financial support: Elizabeth Glaser Pediatric AIDS Foundation; HIV Network for Prevention Trials, sponsored by the National Institute of Allergy and Infectious Disease (NIAID), the National Institutes of Health (NIH), and the Department of Health and Human Services (DHHS), through contracts with Family Health International (NOI-AI-35173), the Fred Hutchinson Cancer Research Center (NOI-AI-45200), and Johns Hopkins University and Makerere University (NOI-AI-35173-417); HIV Prevention Trials Network, sponsored by the NIAID, the National Institutes of Child Health and Human Development (NICH/HD), the National Institute on Drug Abuse, the National Institute of Mental Health, the Office of AIDS Research of the NIH, and the DHHS (U01-AI-46745 and U01-AI-48054); NIAID (Pediatric and Adult AIDS Clinical Trials Groups); NICH/HD (R29 34348); Applied Biosystems (reagents for human immunodeficiency virus genotyping).
PY - 2001/10/1
Y1 - 2001/10/1
N2 - In Uganda, the HIV Network for Prevention Trials (HIVNET) 012 study recently demonstrated that single-dose nevirapine (Nvp) prophylaxis is effective for preventing mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1). This exploratory study examines the relationship between HIV-1 subtype, MTCT, and the development of Nvp resistance (NvpR) in women enrolled in HIVNET 012. For 102 women (32 whose infants were HIV-1 infected by age 6-8 weeks and 70 whose infants were uninfected), HIV-1 subtypes included 50 (49%) subtype A, 35 (34%) subtype D, 4 (4%) subtype C, 12 (12%) recombinant subtype, and 1 unclassified. There was no apparent difference in the rate of MTCT among women with subtype A versus D (adjusted odds ratio [OR], 1.24; 95% confidence interval [CI], 0.45-3.43). NvpR mutations were detected more frequently at 6-8 weeks postpartum in women with subtype D than in women with subtype A (adjusted OR, 4.94; 95% CI, 1.21-20.22). Additional studies are needed to further define the relationship between HIV-1 subtype and NvpR among women receiving Nvp prophylaxis.
AB - In Uganda, the HIV Network for Prevention Trials (HIVNET) 012 study recently demonstrated that single-dose nevirapine (Nvp) prophylaxis is effective for preventing mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1). This exploratory study examines the relationship between HIV-1 subtype, MTCT, and the development of Nvp resistance (NvpR) in women enrolled in HIVNET 012. For 102 women (32 whose infants were HIV-1 infected by age 6-8 weeks and 70 whose infants were uninfected), HIV-1 subtypes included 50 (49%) subtype A, 35 (34%) subtype D, 4 (4%) subtype C, 12 (12%) recombinant subtype, and 1 unclassified. There was no apparent difference in the rate of MTCT among women with subtype A versus D (adjusted odds ratio [OR], 1.24; 95% confidence interval [CI], 0.45-3.43). NvpR mutations were detected more frequently at 6-8 weeks postpartum in women with subtype D than in women with subtype A (adjusted OR, 4.94; 95% CI, 1.21-20.22). Additional studies are needed to further define the relationship between HIV-1 subtype and NvpR among women receiving Nvp prophylaxis.
UR - http://www.scopus.com/inward/record.url?scp=0035479290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035479290&partnerID=8YFLogxK
U2 - 10.1086/323153
DO - 10.1086/323153
M3 - Article
C2 - 11509999
AN - SCOPUS:0035479290
VL - 184
SP - 914
EP - 917
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 7
ER -